Metraipolis › archive › dc_a2e580a28fe5

Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges — Europe PMC PMID:42199864

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42199864
DOI
10.3389/fphar.2026.1822764
License (as archived)
solo-consultazione
Archived
2026-11-02T12:19:51.201Z
SHA-256 of the archived text
22c81dc2009aed7670f19378cfd7c4a2c2d4351d47493c027356d72480a958f3
Stable URL of this page
https://metraipolis.com/documento/dc_a2e580a28fe5

How to cite

Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges — Europe PMC PMID:42199864 — Europe PMC (en), https://europepmc.org/article/MED/42199864 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2e580a28fe5 (Metraipolis archive dc_a2e580a28fe5, sha256 22c81dc2009aed7670f19378cfd7c4a2c2d4351d47493c027356d72480a958f3)
BibTeX
@misc{dca2e580a28fe5,
  title = {Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges — Europe PMC PMID:42199864},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42199864},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2e580a28fe5; sha256 22c81dc2009aed7670f19378cfd7c4a2c2d4351d47493c027356d72480a958f3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42199864. Agents can read the archived copy with the MCP tool read_document.